Monopar Therapeutics (MNPR) vs Shattuck Labs (STTK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Shattuck Labs (STTK) has outperformed Monopar Therapeutics (MNPR) over the past year, gaining 119.7% versus a loss of 24.6%. Over five years, MNPR leads with a +184.5% price change compared with -52.0% for STTK. Monopar Therapeutics is the larger company by market cap ($467.6 million vs $454.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MNPR | STTK |
|---|---|---|
| Share price | $69.00 | $4.46 |
| Market cap | $467.60M | $454.22M |
| 1-day change | -1.84% | -1.98% |
| YTD return | +5.67% | +22.19% |
| 1-year return | -24.64% | +119.70% |
| 5-year return | +184.54% | -51.99% |
| EPS (TTM) | $-2.44 | $-0.47 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $1.00M |
| Revenue growth (YoY) | — | -82.52% |
| Net income (latest FY) | $-13.72M | $-48.81M |
| Operating margin | — | -5150.80% |
| Net margin | — | -4880.90% |
| 52-week high | $124.82 | $8.33 |
| 52-week low | $50.07 | $1.93 |
| Distance from 52-week high | -44.72% | -46.46% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +88.65% | +245.29% |
| Average volume | 151.83K | 1.20M |
| Shares outstanding | 6.78M | 101.84M |
| Employees | 22 | 40 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- STTK has outperformed MNPR by 144.3 percentage points over the past year.
About Monopar Therapeutics
MNPR stock →Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
About Shattuck Labs
STTK stock →Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study.
Health Care · Biotechnology: Pharmaceutical Preparations · 40 employees
MNPR vs STTK FAQ
Which is bigger, Monopar Therapeutics or Shattuck Labs?
Monopar Therapeutics (MNPR) is larger, with a market capitalization of $467.60M compared with $454.22M for Shattuck Labs (STTK).
Which stock has performed better over the past year, MNPR or STTK?
STTK returned +119.70% over the past 12 months, compared with -24.64% for MNPR (price return, excluding dividends). Past performance does not predict future results.
Are Monopar Therapeutics and Shattuck Labs in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.